April 2026 Research Update

This months treatment-focused studies add a practical, real-world picture: care patterns for immune TTP are changing over time, while some hospital treatments appear linked to higher risks in broad inpatient data. Separately, a small set of randomized trial data suggests recombinant ADAMTS13 reliably raises ADAMTS13 levels, but clear proof that it prevents acute TTP events is still not established in the available trials. Together, these studies underline that TTP treatment research is moving in two directions at once: tracking what is happening in everyday hospitals and testing new targeted therapies, with some answers clearer than others. [1] [2] [3]

In nationwide German inpatient data from 2011 to 2021, immune TTP was recorded more often over time, while in-hospital death rates stayed similar, and complications and hospital resource use increased. Over the same period, plasma exchange sessions became fewer on average, rituximab use increased, and caplacizumab (an anti-von Willebrand factor treatment) appeared in about a third of patients in 2020 to 2021. This helps show how newer medicines are being added in routine care, even while overall in-hospital outcomes have not dramatically shifted in this dataset. [1]

A US inpatient database study that grouped TTP together with other platelet-consuming disorders found that hospitalizations with platelet transfusion had higher adjusted odds of in-hospital death and blood clots than hospitalizations without transfusion. The same analysis reported higher odds of clots with intravenous immunoglobulin and lower odds with plasma exchange, but the study cannot prove that any of these treatments caused the outcomes because sicker patients may be more likely to receive certain therapies. For patients, the main takeaway is that large hospital datasets can spot risk patterns, but they do not answer the personal question of whether a given treatment was the right choice in a specific emergency. [2]

A systematic review of 2 randomized trials (129 patients with congenital or acquired TTP) found recombinant ADAMTS13 increased measured ADAMTS13 activity compared with standard therapy or placebo. In these trials, it did not show a statistically clear reduction in acute TTP events or serious treatment-emergent adverse events, while urticaria (hives) was reported less often with recombinant ADAMTS13. This adds clarity that the medicine does what it is designed to do biologically (raise ADAMTS13 levels), while the size of real-world clinical benefit still needs larger trials to sort out. [3]

One additional paper this month was a chapter describing therapeutic plasma exchange as a central part of immune TTP care, including how teams manage procedures and complications. It does not report new outcome results, but it reflects the ongoing focus on delivering plasma exchange safely and consistently in practice. For readers, it helps explain why plasma exchange remains a core part of immune TTP treatment even as other medicines are added. [4]

For patients and caregivers, this body of work mostly adds context rather than changing what can be concluded right now about the best approach for an individual. The strongest immediate information here is descriptive: hospitals are using rituximab and caplacizumab more often over time in Germany, and plasma exchange sessions have decreased, while in-hospital mortality in that dataset stayed stable. The transfusion analysis raises an important safety question to study further, but it is not designed to show that transfusions themselves cause harm. The recombinant ADAMTS13 trials give a clearer signal about biology (higher ADAMTS13 levels) than about preventing acute attacks, which remains uncertain at this stage. [1] [2] [3] [4]

What became clearer this month is that progress in TTP treatment is being measured in different ways at once: population data show how care is shifting, while randomized trials are still building evidence for newer targeted treatments. It also becomes clearer why emergency decisions can look different across hospitals, because patients vary in severity and treatments are often layered together. What remains uncertain is how much each individual treatment (including platelet transfusion in mixed TTP-related hospital groups, or recombinant ADAMTS13 in small trials) changes outcomes when separated from the underlying illness severity. [1] [2] [3]

This month includes a focused look at day-to-day health in hereditary TTP, and the message is steady rather than dramatic: patients reported ongoing burdens that did not improve much over a year. Fatigue, mood symptoms, and thinking or memory difficulties were common in these reports, while positive feelings were closer to the general population average. This kind of research matters because it measures parts of the illness that routine lab results may not capture. [5]

In a small prospective study from the International Hereditary TTP Registry, baseline patient-reported scores were worse than the US general population for fatigue, depression, anxiety, and cognitive function, and these differences persisted at 6 and 12 months. The study also noted that these scores were similar to, or worse than, published data from immune-mediated TTP and other chronic diseases. For patients, this strengthens the message that hereditary TTP can affect quality of life in ongoing ways, not only during acute medical events. [5]

For patients and caregivers, this study mainly adds understanding rather than changing diagnosis or treatment. It puts numbers on experiences that many people describe, like persistent fatigue and problems with concentration, and it shows these concerns may remain fairly stable over 1 year in the group studied. What remains uncertain is how these symptoms relate to specific medical factors (like lab results or treatment timing), because this report measured symptoms but did not test ways to improve them. [5]

Several reports this month highlight that a TTP-like emergency can have very different underlying causes, and the early clues may be an unusual course or an unexpected lab pattern. Across these cases, the shared lesson is that looking beyond the label can matter, because the best next steps depend on what is truly driving the problem. These reports do not change how often these situations happen, but they make the range of look-alike conditions more concrete. [6] [7] [8] [9] [10] [11]

Two case reports described severe vitamin deficiencies (vitamin B12, and vitamin B12 plus folate) causing a pseudo-thrombotic microangiopathy that mimicked TTP. In one report, the authors emphasized that pseudo-TMA patients are often clinically stable without the kidney or neurologic problems more typical of TTP, and they highlighted lab features used to separate the conditions. In the other report, blood counts and hemolysis improved rapidly after targeted vitamin replacement, showing that the condition can be reversible when the underlying deficiency is corrected. [6] [7]

Another case report described acquired TTP with poor response to standard therapy where further evaluation uncovered an aggressive metastatic signet ring cell cancer, and the patient died within a week. The report argues that an atypical or worsening course should raise suspicion for an underlying trigger such as an occult malignancy. For patients, it is a reminder that the same low-platelet and anemia pattern can sometimes be driven by serious underlying disease that is not obvious at first. [8]

A separate case report described thrombotic thrombocytopenic purpura developing during treatment of triple-negative breast cancer with a PD-L1 inhibitor plus taxane chemotherapy. The authors emphasized paying attention to new or worsening anemia and low platelets during these treatments as a prompt to evaluate for thrombotic microangiopathy. This expands the list of situations where clinicians may need to consider a TTP-like process, although one case cannot show how common it is. [9]

A small case-series of 3 pregnant women with thrombotic microangiopathy in a resource-limited setting reported that all received urgent therapeutic plasma exchange, using a resource-adapted approach because specialized tests and eculizumab were not available. Two cases were considered likely complement-mediated HUS rather than TTP, and one patient had a known hereditary thrombocytopenic purpura history. The main contribution is showing how diagnostic uncertainty and limited access to testing can shape care pathways in pregnancy-related microangiopathy. [10]

One additional case report described a patient with clinical features of TTP where standard clotting tests were normal, but von Willebrand factor activity was markedly decreased later in the hospital course. The report highlights that individual lab patterns can sometimes look paradoxical, which can complicate interpretation in real time. For patients, it underscores that TTP involves the von Willebrand factor system in complex ways that are not always reflected by a single expected lab direction. [11]

For patients, these reports mainly matter as background understanding: TTP symptoms and lab changes can be imitated by vitamin deficiencies, pregnancy-related conditions, cancer, or cancer treatments. This does not provide a rule for self-identifying the cause, but it helps explain why teams may run broad tests when the course is unusual or when the response to initial treatment is not as expected. What remains uncertain is how often each of these causes occurs, because case reports and small series cannot estimate frequency. [6] [7] [8] [9] [10] [11]

This month includes several laboratory and method papers aimed at measuring ADAMTS13 function and immune activity in more nuanced ways than a single activity level. The shared direction is toward tests that may help separate immune TTP biology from look-alike conditions, and possibly track relapse risk, but these are still research tools rather than proven routine tests. Collectively, they show that researchers are trying to capture how ADAMTS13 behaves in the body, under flow, and under attack from antibodies. [12] [13] [14]

One paper described an assay to detect the open form of ADAMTS13 in plasma, proposing it as a biomarker for immune TTP and for relapse prediction. The key idea is that ADAMTS13 can shift shape, and the open form may appear when it binds von Willebrand factor or when anti-ADAMTS13 antibodies bind it. For patients, this represents an attempt to turn a complex immune process into a measurable signal, although the report did not provide clinical performance results in the summary provided. [12]

Two additional method papers focused on how ADAMTS13 works and is blocked. One described a way to measure how strongly and how quickly anti-ADAMTS13 antibodies inhibit the enzyme, which could help classify immune responses in iTTP. Another described a microfluidic flow-based system to visualize platelet and von Willebrand factor interactions under arterial-like flow and to test agents such as recombinant ADAMTS13 and caplacizumab within that system. [13] [14]

For patients and caregivers, these method studies are mainly early research that could matter later if they lead to more accurate or faster testing for immune TTP, or better ways to predict relapse. They do not by themselves show that outcomes improve, and they are not presented as standard-of-care tests in the information provided. What they do clarify now is that immune TTP is being studied at a deeper level than just a single ADAMTS13 activity number, including the enzymes shape, how antibodies block it, and how it functions under blood flow conditions. [12] [13] [14]

This month adds early signals for future immune-targeted approaches in immune TTP, ranging from a laboratory proof-of-concept to individual patient experience in a refractory case. The common idea is selective control of the immune process that attacks ADAMTS13, but the evidence is still early and not comparable across studies. These reports mainly show what is technically possible and what has been tried when standard approaches are not enough. [15] [16]

In laboratory testing, reverse CAR (RevCAR) T cells were engineered to kill CD19-positive B cells and anti-ADAMTS13 autoreactive B cells, using bridging molecules (RevTMs) to direct the attack. The study reported that these RevCAR T cells killed target cells in a RevTM-dependent way and could do so even when high levels of ADAMTS13 autoantibodies were present. For patients, this is a research-stage approach that aims to more precisely remove the immune cells involved in iTTP, but it is not a human treatment result. [15]

A single case report described refractory immune TTP where caplacizumab was added after plasma exchange and glucocorticoids, alongside rituximab. After caplacizumab was added, platelet count and LDH normalized rapidly, ADAMTS13 activity rose to 24.9%, and no serious adverse events were reported in that patient. This case supports the idea that caplacizumab can be used as an add-on in difficult situations, while also underscoring that one patients course cannot predict what will happen for others. [16]

For patients, these studies are best viewed as early steps toward more targeted immune control in iTTP rather than settled evidence. The RevCAR T-cell work may matter in the future if it can be translated into safe human studies, but for now it remains laboratory research. The caplacizumab case report adds a real-world example of improvement in a refractory situation, but it cannot answer questions like how often this happens or who is most likely to benefit. [15] [16]